Current treatment of psoriasis with biologics

Current Drug Discovery Technologies

Volumn 6, Issue 4, 2009, Pages 231-240

  Kunz, Manfred ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Antibodies; Autoimmunity; Chronic inflammation; Clinical trials; Th17 cells

Indexed keywords

ADALIMUMAB; AIN 457; ALEFACEPT; ANTIPSORIASIS AGENT; BETA DEFENSIN 2; CD68 ANTIGEN; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17F; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PSORALEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ANTIGEN PRESENTING CELL; ARTHRALGIA; BIOLOGICAL THERAPY; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATINE KINASE BLOOD LEVEL; CYTOKINE PRODUCTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; GENE EXPRESSION; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOCYTOPENIA; MACROPHAGE; MONOCYTE; MONOTHERAPY; NAUSEA; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UPREGULATION; VOMITING;

BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; PSORIASIS; RECOMBINANT PROTEINS;

EID: 70449718874     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016309789869092     Document Type: Review

References (78)

1. Schön MP, Boehncke WH. Psoriasis. New Engl J Med 2005; 352(18): 1899-1912
2. Langley RG, Krueger GG, Griffiths CE. Psoriasis: Epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64(Suppl 2): ii18-23.
3. Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53(1 Suppl 1): S94-100. (Pubitemid 40828186)
4. Nair RP, Ding J, Duffin KC, et al. Psoriasis bench to bedside: Genetics meets immunology. Arch Dermatol 2009; 145(4): 462-464
5. Krueger JG, Bowcock A. Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis 2005; 64(Suppl 2): ii30-6. (Pubitemid 40288517)
6. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156(2): 271-276 (Pubitemid 46095954)
7. Ortonne JP. Psoriasis, metabolic syndrome and its components. Ann Dermatol Vénéréol 2008; 135(Suppl 4): 235-242
8. Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144(12): 1571-1575
9. Gerdes S, Zahl VA, Knopf H, et al. Comedication related to comorbidities: A study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008; 159(5): 1116-1123
10. Bos JD, de Rie MA. The pathogenesis of psoriasis: Immunological facts and speculations. Immunol Today 1999; 20(1): 40-46
11. Bowcock AM. The genetics of psoriasis and autoimmunity. Annu Rev Genomics Hum Genet 2005; 6: 93-122.
12. Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: Therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006; 18(6): 670-675
13. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199(1): 125-130 (Pubitemid 38076484)
14. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: Current prospects. J Am Acad Dermatol 2007; 57(6): 1059-1068
15. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin. J Immunol 2006; 176(3): 1908-1915
16. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445(7128): 648-651 (Pubitemid 46232884)
17. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 + T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278(3): 1910-1914 (Pubitemid 36801431)
18. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13(5): 715-725
19. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007; 13(3): 242-244
20. Moser KL, Gaffney PM, Grandits ME, et al. The use of microarrays to study autoimmunity. J Invest Dermatol Symp Proc 2004; 9(1): 18-22.
21. Chung CH, Levy S, Chaurand P, Carbone DP. Genomics and proteomics: Emerging technologies in clinical cancer research. Crit Rev Oncol Hematol 2006; 61(1): 1-25. (Pubitemid 44880146)
22. Centola M, Frank MB, Bolstad AI, et al. Genome-scale assessment of molecular pathology in systemic autoimmune diseases using microarray technology: A potential breakthrough diagnostic and individualized therapy-design tool. Scand J Immunol 2006; 64(3): 236-242 (Pubitemid 44215113)
23. Draghici S, Khatri P, Eklund AC, et al. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 2006; 22(2): 101-109 (Pubitemid 43152029)
24. Bowcock AM, Shannon W, Du F, et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 2001; 10(17): 1793-1805 (Pubitemid 32899097)
25. Oestreicher JL, Walters IB, Kikuchi T, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001; 1(4): 272-287 (Pubitemid 33756652)
26. Quekenborn-Trinquet V, Fogel P, Aldana-Jammayrac O, et al. Gene expression profiles in psoriasis: Analysis of impact of body site location and clinical severity. Br J Dermatol 2005; 152(3): 489-504. (Pubitemid 40547123)
27. Zhou X, Krueger JG, Kao MC, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003; 13(1): 69-78. (Pubitemid 37129170)
28. Koczan D, Guthke R, Thiesen HJ, et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005; 15(4): 251-257 (Pubitemid 41020851)
29. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51(4): 563-569
30. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60(4): 643-659
31. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61(3): 451-485
32. Krueger GG. Clinical features of psoriatic arthritis. Am J Manag Care 2002; 8(6 Suppl): S160-70.
33. Mittal R, Malhotra S, Pandhi P, Kaur I, Dogra S. Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: A randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 2009; 145(4): 387-393
34. Lin YK, Chang CJ, Chang YC, Wong WR, Chang SC, Pang JH. Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis. Arch Dermatol 2008; 144(11): 1457-1464
35. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2(8657): 244-247 (Pubitemid 19180612)
36. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2(5): 364-371 (Pubitemid 37328759)
37. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics. Immunol Rev 2008; 223: 7-19. (Pubitemid 351986171)
38. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Over-view of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5): 826-850
39. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58(5): 851-864
40. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345(4): 248-255
41. Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A. Treatment of psoriasis with alefacept: Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003; 139(12): 1563-1570 (Pubitemid 37523074)
42. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47(6): 821-833
43. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebocontrolled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139(6): 719-727 (Pubitemid 36705938)
44. Menter A, Cather JC, Baker D, Farber HF, Lebwohl M, Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006; 54(1): 61-63 (Pubitemid 41832458)
45. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349(21): 2004-2013 (Pubitemid 37448923)
46. Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005; 52(3 Pt 1): 425-433
47. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: Results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008; 158(5): 1107-1116
48. Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: An advisory group report. J Am Acad Dermatol 2006; 54(4 Suppl 1): S171-81. (Pubitemid 43238300)
49. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356(9227): 385-390 (Pubitemid 30487495)
50. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139(12): 1627-1632 (Pubitemid 37523083)
51. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152(6): 1304-1312 (Pubitemid 40933433)
52. Gottlieb AB, Leonardi CL, Goffe BS, et al. Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006; 54(3 Suppl 2): S92-100.
53. Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003; 48(1): 68-75. (Pubitemid 36091536)
54. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52(4):1227-1236 (Pubitemid 40530131)
55. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaquetype psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51(4): 534-542 (Pubitemid 39278071)
56. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 2005; 366(9494): 1367-1374 (Pubitemid 41443403)
57. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52(10): 3279-3289 (Pubitemid 41447111)
58. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2007; 58(1): 106-115 (Pubitemid 350298146)
59. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158(3): 558-566 (Pubitemid 351239154)
60. Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003; 29(1): 185-202. (Pubitemid 36298110)
61. Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: A report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009; 160(1): 8-15.
62. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62(7): 686-687 (Pubitemid 36760576)
63. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359(9306): 579-580 (Pubitemid 34178442)
64. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel. Semin Arthritis Rheum 2005; 34(6): 819-836
65. Bartlett BL, Tyring S.K. Ustekinumab for chronic plaque psoriasis. Lancet 2008; 371(9625): 1639-1640
66. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371(9625): 1665-1674 (Pubitemid 351671883)
67. Papp KA, Langley RG, Lebwohl M, et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371(9625): 1675-1684 (Pubitemid 351671884)
68. O'Neill JL, Kalb RE. Ustekinumab in the therapy of chronic plaque psoriasis. Biologics 2009; 3: 159-168
69. Chatenoud L. Immune therapies of autoimmune diseases: are we approaching a real cure? Curr Opin Immunol 2006; 18(6): 710-717
70. Finckh A, Gabay C. At the horizon of innovative therapy in rheumatology: New biologic agents. Curr Opin Rheumatol 2008; 20(3): 269-275
71. Scheinecker C, Redlich K, Smolen JS. Cytokines as therapeutic targets: Advances and limitations. Immunity 2008; 28(4): 440-444
72. Elliott MJ, R.N. Maini, M. Feldmann, et al. Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344(8930): 1105-1110
73. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201(9): 1479-1486 (Pubitemid 40664091)
74. González-López MA, Martínez-Taboada VM, González-Vela MC, Fernández-Llaca H, Val-Bernal JF. New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br J Dermatol 2008; 158(5): 1146-1148
75. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66(9): 1162-1167 (Pubitemid 47309731)
76. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58(10): 2968-2980
77. Baslund B, Tvede N, Danneskiold-Samsoe B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study. Arthritis Rheum 2005; 52(9): 2686-2692 (Pubitemid 41369096)
78. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367(9504): 29-35. (Pubitemid 43038667)